Suzhou Yabao pharmaceutical R & D Co., Ltd. (hereinafter referred to as "Suzhou Yabao") officially settled in the biological nano Park of Suzhou Industrial Park in April 2014. It is a holding subsidiary of Yabao Pharmaceutical Group, a well-known domestic listed pharmaceutical company, with a registered capital of 10 million yuan and a R & D platform of 1700 square meters
adhering to the concept of "innovation, openness and cooperation", Suzhou Yabao adheres to the path of international cooperation, globally selects potential new drugs and related patents, and carries out new drug research and development through the strategy of obtaining rights and interests in China and cooperating with world-famous pharmaceutical enterprises and academic institutions, so as to research and develop truly meaningful international innovative drugs
Suzhou Yabao is committed to the development and international cooperation of class 1 innovative drugs. The company has established cooperative relations with Lilly pharmaceutical, the University of South Australia, the University of Western Ontario, the Department of science and Technology (MRCT) of British Medical College and other world-famous enterprises and colleges. At present, Suzhou Yabao has 10 class I innovative drug research projects, of which 5 have been promoted to phase I-II clinical, and all projects are in the forefront of the world
at present, the company has more than 30 employees, with more than 80% of them with master's degree or above and more than 20% of them with overseas returnees and doctoral degrees. The team has successful experience in Sino US bilateral innovative drug development and international cooperation. At present, the company has obtained 10 authorized patents (including 3 PCT patents), all of which are invention patents.